Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Average Price Target of $6.40

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.40.

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. Cantor Fitzgerald assumed coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They set an “overweight” rating and a $3.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $0.66 on Tuesday. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The firm’s 50-day moving average is $0.82 and its two-hundred day moving average is $1.32. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.82 million. Equities research analysts expect that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. HighTower Advisors LLC boosted its position in shares of Milestone Pharmaceuticals by 100.0% during the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after purchasing an additional 10,000 shares in the last quarter. Welch & Forbes LLC acquired a new stake in Milestone Pharmaceuticals during the first quarter valued at approximately $30,000. Bay Rivers Group lifted its stake in Milestone Pharmaceuticals by 55.9% during the second quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock valued at $62,000 after purchasing an additional 16,722 shares during the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new stake in Milestone Pharmaceuticals during the third quarter valued at approximately $68,000. Finally, ADAR1 Capital Management LLC bought a new stake in Milestone Pharmaceuticals during the second quarter worth approximately $134,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s research is centered on treatments designed to provide rapid, patient-administered relief for episodic cardiovascular disorders. Milestone’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. The therapy has been developed primarily for the treatment of paroxysmal supraventricular tachycardia, or PSVT, a condition characterized by episodes of abnormally rapid heart rate.